Marco Ravanelli1, Giorgio M Agazzi1, Balaji Ganeshan2, Elisa Roca3, Elena Tononcelli4, Valeria Bettoni1, Alberto Caprioli5, Andrea Borghesi1, Alfredo Berruti3, Roberto Maroldi1, Davide Farina1. 1. University of Brescia, Department of Radiology, Piazzale Spedali Civili 1, 25123 Brescia, Italy. 2. Institute of Nuclear Medicine, University College, London, UK. 3. University of Brescia, Department of Oncology, Piazzale Spedali Civili 1, 25123 Brescia, Italy. 4. University of Brescia, Department of Radiology, Piazzale Spedali Civili 1, 25123 Brescia, Italy. Electronic address: tononcelli.elena@gmail.com. 5. University of Brescia, Department of Pneumology, Piazzale Spedali Civili 1, 25123 Brescia, Italy.
Abstract
PURPOSE: To assess the predictive and prognostic value of pre-treatment CT texture features in lung adenocarcinoma treated with tyrosine kinase inhibitors (TKI). MATERIALS AND METHODS: Texture analysis was performed using commercially available software (TexRAD Ltd, Cambridge, UK) on pre-treatment contrast-enhanced CT studies from 50 patients with metastatic lung adenocarcinoma treated by TKI. Texture features were quantified on a 5-mm-thick central slice of the primary tumor and were correlated with progression-free and overall survival (PFS and OS) using an internally cross-validated machine learning approach then validated on a bootstrapped sample. RESULTS: Median PFS and OS were 10.5 and 20.7 months, respectively. A noninvasive signature based on five texture parameters predicted 6-month progression with Area Under the Curve (AUC) of 0.8 (95% CI) and 1-year progression with AUC of 0.76. A high-risk group had hazard ratios for progression of 4.63 and 5.78 when divided by median and best cut-off points, respectively. Texture signature did not correlate with OS. Available clinical variables did not correlate with PFS or with OS. CONCLUSION: Texture features seem to be associated with PFS in lung adenocarcinoma treated with TKI.
PURPOSE: To assess the predictive and prognostic value of pre-treatment CT texture features in lung adenocarcinoma treated with tyrosine kinase inhibitors (TKI). MATERIALS AND METHODS: Texture analysis was performed using commercially available software (TexRAD Ltd, Cambridge, UK) on pre-treatment contrast-enhanced CT studies from 50 patients with metastatic lung adenocarcinoma treated by TKI. Texture features were quantified on a 5-mm-thick central slice of the primary tumor and were correlated with progression-free and overall survival (PFS and OS) using an internally cross-validated machine learning approach then validated on a bootstrapped sample. RESULTS: Median PFS and OS were 10.5 and 20.7 months, respectively. A noninvasive signature based on five texture parameters predicted 6-month progression with Area Under the Curve (AUC) of 0.8 (95% CI) and 1-year progression with AUC of 0.76. A high-risk group had hazard ratios for progression of 4.63 and 5.78 when divided by median and best cut-off points, respectively. Texture signature did not correlate with OS. Available clinical variables did not correlate with PFS or with OS. CONCLUSION: Texture features seem to be associated with PFS in lung adenocarcinoma treated with TKI.
Authors: Hannah Able; Amber Wolf-Ringwall; Aaron Rendahl; Christopher P Ober; Davis M Seelig; Chris T Wilke; Jessica Lawrence Journal: PLoS One Date: 2021-08-17 Impact factor: 3.240
Authors: Balaji Ganeshan; Kenneth Miles; Asim Afaq; Shonit Punwani; Manuel Rodriguez; Simon Wan; Darren Walls; Luke Hoy; Saif Khan; Raymond Endozo; Robert Shortman; John Hoath; Aman Bhargava; Matthew Hanson; Daren Francis; Tan Arulampalam; Sanjay Dindyal; Shih-Hsin Chen; Tony Ng; Ashley Groves Journal: Cancers (Basel) Date: 2021-05-31 Impact factor: 6.639